Vanderbilt-Ingram Cancer Center: Head and Neck Neoplasms trials

The registry lists 28 Head and Neck Neoplasms studies with Vanderbilt-Ingram Cancer Center as lead sponsor. 5 are open to participants now and 5 have results posted.

Early Phase 1 1Phase 1 3Phase 2 3Phase 3 1No phase 20(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and [18F]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head and Neck Squamous Cell CarcinomaRecruitingNCT07741643Phase 1
• Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingNCT07741565Early Phase 1
• Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC)RecruitingNCT07460765Phase 1
• High-Resolution PET-CT Imaging for Surgical Margin VisualizationRecruitingNCT06915454Not applicable
• Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck CancerRecruitingNCT06819228Phase 1
• Central Pain Syndrome in Survivors of Head and Neck CancerTerminatedNCT04128267Not applicableResults posted
• Gabapentin Compared to Standard of Care in Preventing Mucositis in Patients With Stage III-IV Head and Neck Cancer Undergoing Primary or Adjuvant Chemoradiation TherapyCompletedNCT02480114Phase 3Results posted
• Irinotecan and Cisplatin in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00639769Phase 2Results posted
• Pemetrexed and Oxaliplatin in Treating Patients With Locally Advanced Head and Neck CancerCompletedNCT00503997Phase 2Results posted
• Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck CancerCompletedNCT00425750Phase 2Results posted
• Yoga Intervention in Head and Neck Cancer Patients Undergoing Concurrent Chemo-RadiationTerminatedNCT04146779Not applicable
• Skin/Soft Tissue Elasticity in Head and Neck Cancer Survivors With Lymphedema and FibrosisCompletedNCT02676752
• Pain Management Smartphone Application for Patients With Stage III-IV Head and Neck Cancer Undergoing Radiation TherapyCompletedNCT02324881Not applicable
• Home-Based Lymphedema Care Program (HBLCP) in Improving Lymphedema Self-Care in Head and Neck Cancer SurvivorsTerminatedNCT02170272Not applicable
• Feasibility and Preliminary Efficacy of Hatha Yoga in Head and Neck Cancer SurvivorsCompletedNCT01951664Not applicable
• Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid TumorTerminatedNCT01096381
• Protein Expression in Tumor Tissue Samples From Patients With Cancer of the OropharynxCompletedNCT00899340
• Gene and Protein Expression Patterns in Predicting Response to Cetuximab in Patients With Recurrent and/or Metastatic Head and Neck CancerTerminatedNCT00898742
• DNA Analysis of Tissue Samples From Patients With Head and Neck CancerCompletedNCT00898664
• Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation TherapyTerminatedNCT00898430
• Growth Factor Levels in the Blood of Patients Undergoing Radiation Therapy for Epithelial CancerCompletedNCT00897793
• Gene Expression Profiles in Predicting Survival of Patients With Head and Neck CancerCompletedNCT00897052
• Immunoreactivity to Cetuximab in Cancer PatientsCompletedNCT00896896
• Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell CancerCompletedNCT00896675
• Investigation of Pain and Symptom Burden in Patients With Newly Diagnosed Head and Neck CancerCompletedNCT00655005
• Family Quality of Life Among Families With a Member Who is a Cancer PatientCompletedNCT00544336
• A Retrospective Analysis of Neck Dissection Following Complete Response to Chemoradiation in HNSCCCompletedNCT00483821
• Study of Anxiety and Avoidance of Others in Patients Previously Treated for Head and Neck CancerCompletedNCT00483639